Restless legs: why treatment guidance changed

The 2012 AASM restless-legs guideline treated dopamine agonists as first-line medicine. The 2025 guideline reversed that. Winkelman and colleagues now suggest against the routine use of pramipexole and ropinirole because of augmentation. The strong recommendations are gabapentin enacarbil, gabapentin, pregabalin, and intravenous ferric carboxymaltose, plus a good-practice iron workup in everyone with clinically significant RLS. If your refill still looks like 2012, that is the problem this page is about.

What exactly reversed between 2012 and 2025?

The current document is Winkelman JW and colleagues, “Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline,” Journal of Clinical Sleep Medicine 2025;21(1):137–152 (doi 10.5664/jcsm.11390). It was posted as an accepted paper on 26 September 2024 and scheduled for the 1 January 2025 issue. It contains 28 GRADE recommendations and updates the 2012 CPG.

In 2012, pramipexole and ropinirole carried strong recommendations for use. They were the default prescription in primary care and in many sleep clinics for two decades. In the 2025 paper, both are CONDITIONAL recommendations against standard use (moderate certainty). Transdermal rotigotine is CONDITIONAL against standard use (low certainty). Levodopa is CONDITIONAL against. Cabergoline is a STRONG recommendation against. The AASM summary by Berkowski and Winkelman is direct: with augmentation counted as a critical outcome, the balance of effects for dopaminergic agents shifted toward long-term harm.

That is not a minor wording tweak. It is the reason a patient who has been “stable on pramipexole for years” needs a different conversation than the one they had in 2015. The restless legs condition page states the current regimen. This article is about why the old regimen was withdrawn from routine use, and what “augmentation” actually means, so that a 2012 printout is not treated as current care.

What is augmentation, and why did short trials miss it?

Augmentation is iatrogenic worsening from dopaminergic therapy. Symptoms start earlier in the day, spread to body parts that were not involved, and become more intense. It develops over months to years. Registration trials that lasted a few weeks or months did not capture it. Berkowski and Winkelman’s AASM summary is explicit on that timeline. When a clinician answers worsening RLS by raising the dopamine-agonist dose, they can feed the same process. CHEST Physician commentary on the guideline (Tobias and Koo, 2025) notes that once the dose is at or above the labeled RLS maxima they cite (4.0 mg ropinirole, 0.75 mg pramipexole, 3 mg rotigotine), augmentation is very likely. Treating it means tapering the dopaminergic drug off while starting a non-dopaminergic alternative. That is specialist work, not a blog taper schedule.

The 2025 remarks on pramipexole and ropinirole leave a values-based exception: those drugs may still be used in patients who place a higher value on short-term symptom relief and a lower value on long-term adverse effects, particularly augmentation. That is an exception, not a selling point. The AASM press release is equally clear that alpha-2-delta ligands are not associated with the augmentation seen with dopaminergic agents.

Do not stop a dopamine agonist this afternoon because you read this. Impulse-control problems and rebound are real. The visit is where you decide whether you are already augmented, whether a gabapentinoid is the next step, and how to change the prescription without a week of pacing the hallway.

What does the 2025 guideline recommend instead?

Four STRONG recommendations for adults with RLS, all moderate certainty, from the published list:

• Gabapentin enacarbil over no gabapentin enacarbil. This is the only remaining FDA-approved RLS drug that is strongly recommended in the CPG, per the AASM summary.
• Gabapentin over no gabapentin.
• Pregabalin over no pregabalin.
• Intravenous ferric carboxymaltose over no IV FCM, in patients with appropriate iron status as defined in the good-practice statement.

Those three gabapentinoids are alpha-2-delta ligand calcium-channel modulators. The AASM press release and the Berkowski–Winkelman summary group them together: benefits for severity, sleep, and quality of life outweighed sedation and gait instability in the task force’s judgment. They can still cause those adverse effects. They are first-line now. Dopamine agonists are not.

CONDITIONAL options in adults include IV low-molecular-weight iron dextran, IV ferumoxytol, oral ferrous sulfate (with appropriate iron status), dipyridamole, extended-release oxycodone and other opioids, and bilateral high-frequency peroneal nerve stimulation. Opioids come with explicit caution; a national RLS opioid registry based at Massachusetts General Hospital continues to collect long-term data. Cabergoline is out. Clonazepam, once a common add-on, is CONDITIONAL against. So are bupropion, carbamazepine, valerian, and valproic acid, at various certainty levels.

In children, ferrous sulfate is the only recommended treatment, and it is CONDITIONAL. Pregnancy is flagged: RLS is common, and prescribers should use pregnancy-specific safety information rather than copying an adult gabapentinoid plan from a blog.

What iron tests, and is ferritin 75 μg/L in the guideline?

Yes. The CPG’s good-practice statement, as published in the Europe PMC full recommendation list, says clinicians should regularly test serum iron studies, including ferritin and transferrin saturation (calculated from iron and TIBC), in all patients with clinically significant RLS. Testing should ideally be in the morning, avoiding iron-containing supplements and foods for at least 24 hours. Consensus guidelines, which the task force notes have not been empirically tested, suggest iron supplementation in adults if serum ferritin is ≤ 75 ng/mL (the same numeric value as 75 μg/L) or transferrin saturation is under 20 percent, using oral or IV iron; and only IV iron if ferritin is between 75 and 100 ng/mL. In children, supplementation is suggested for ferritin under 50 ng/mL. Those targets are different from general-population anemia cutoffs. Low brain iron is treated as an important mechanism, which is why a “normal” ferritin for a primary-care anemia screen can still be too low for RLS.

CHEST Physician’s 2025 commentary used the same 75 μg/L figure and added a practical point: oral ferrous sulfate when ferritin is below 75 μg/L; IV iron preferred when ferritin sits between 75 and 100 μg/L because oral absorption is poor in that range. IV ferric carboxymaltose has a STRONG recommendation based on randomized trials. Tobias and Koo note that this formulation is often unavailable in infusion centers, which is why the CPG also offers CONDITIONAL IV alternatives. Older fears of IV iron anaphylaxis were driven largely by high-molecular-weight iron dextran that is no longer used in the United States.

Iron is not optional color on the lab slip. It is the first management step the press release elevates, together with taking away exacerbants.

What should happen before a new prescription?

The good-practice statement’s first management step is to address exacerbating factors: alcohol, caffeine, antihistaminergic, serotonergic, and antidopaminergic medications, and untreated obstructive sleep apnea. Over-the-counter nighttime antihistamines are a frequent aggravator. Many antidepressants can worsen RLS; the CHEST commentary is more pointed about drugs with antihistaminergic properties (mirtazapine, doxepin, other tricyclics) when RLS is severe. Untreated apnea makes RLS harder to control, and treating apnea can be enough when RLS is infrequent.

RLS is a clinical diagnosis. It does not require a sleep study, though periodic limb movements are often seen if a study is done for another reason. Severity ranges from occasional nuisance to nightly pacing. Not everyone needs a daily drug. Occasional symptoms that do not block sleep may not need anything beyond trigger removal and iron if stores are low.

Bring a medication list that includes the dopamine agonist dose and start date, any recent increases, and the clock time symptoms now begin. Dr. Mahmoud Qadoom can sort whether this is untreated RLS, augmentation, iron deficiency, apnea, or a mix. Book through appointments or call (614) 898-9340 during weekday hours. Do not describe symptoms in a website form. Do not treat a 2012 patient-handout as current guidance. The 2025 CPG is the document that applies now.